Sheehan's syndrome pathophysiology

Jump to navigation Jump to search

Sheehan's syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sheehan's syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sheehan's syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sheehan's syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sheehan's syndrome pathophysiology

CDC on Sheehan's syndrome pathophysiology

Sheehan's syndrome pathophysiology in the news

Blogs on Sheehan's syndrome pathophysiology

Directions to Hospitals Treating Sheehan's syndrome

Risk calculators and risk factors for Sheehan's syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

  • The exact pathogenesis of [disease name] is not fully understood.

OR

  • It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
  • [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
  • Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
  • [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
  • The progression to [disease name] usually involves the [molecular pathway].
  • The pathophysiology of [disease/malignancy] depends on the histological subtype.

Pathophysiology

Pathogenesis

Pituitry gland is amongst the most vascularized tissues in the body that normally weighs about 0.5g but gets doubled in size during pregnancy. Pituitary gland enlargement due to hypertrophy and hyperplasia[1] of lactotrophic cells in anterior pituitary and decreased portal pressure play an important role in the pathogenesis of Sheehan syndrome. Severe PPH leading to hypotension and ischemic necrosis of pituitary gland is the most common cause of Sheehan syndrome.[2] Apart from pituitary gland enlargement during and before parturition, vasospasm, thrombosis and compression of the hypophyseal arteries, autoimmunity, DIC and smaller size of sella are thought to play a contributing role in pathogenesis of sheehan Syndrome.[2] It is thought that tissue necrosis results in release of sequestered antigens, precipitating autoimmunity of the pituitary gland and hypopituitarism in Sheehan's syndrome.[3] Type 1 diabetes, pre-existinfg vascular diseases and known/unknown pituitary masses are associated with increased risk of developing Sheehan syndrome in pregnancy [4] Anterior pituitary does not have a direct blood supply and is supplied by hypophyseal portal system. The hypophyseal portal system is a fenestrated set of capillaries and allows rapid exchange of hormones between hypothalamus and anterior pituitary. Occlusions and other issues in the blood vessels of the hypophyseal portal system can also cause complications in the exchange of hormones between the hypothalamus and the pituitary gland leading to hypopituitarism.

Genetics

  • [Disease name] is transmitted in [mode of genetic transmission] pattern.
  • Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
  • The development of [disease name] is the result of multiple genetic mutations.

Associated Conditions

Gross Pathology

  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

On microscopy, the following findings may be observed:

  • Ischemic necrosis leading to scarring of neurohypophysis
  • Scarring of para-ventricular and supra-optic nuclei

References

  1. Scheithauer BW, Sano T, Kovacs KT, Young WF, Ryan N, Randall RV (1990). "The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases". Mayo Clin. Proc. 65 (4): 461–74. PMID 2159093.
  2. 2.0 2.1 Keleştimur F, Chow YW, Pietranico R, Mukerji A, Wiesmann UN, DiDonato S, Herschkowitz NN, Voigt WG, Johnson CR, Moroi K, Sato T, Keleştimur F, Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N, Wrightstone RN, Smith LL, Wilson JB, Vella F, Huisman TH, Marniemi J, Parkki MG, Ward CW, Stellwagen E, Babul J, Pogodina VV, Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N, Schmoldt A, Benthe HF, Haberland G, Lyons HA, Thomas JS, Heurich AE, Shepherd DA, Wetmore SD, Mekler LB, Sealey JE, White RP, Laragh JH, Rubin AL, Makar AB, McMartin KE, Palese M, Tephly TR, Frankle RT, Makar AB, McMartin KE, Palese M, Tephly TR, Makar AB, McMartin KE, Palese M, Tephly TR, Makar AB, McMartin KE, Palese M, Tephly TR, Makar AB, McMartin KE, Palese M, Tephly TR, Frankle RT, Thornton JA, Harrison MJ, Stellwagen E, Babul J, Leroy M, Loas G, Perez-Diaz F, Schmoldt A, Benthe HF, Haberland G, Coller BS, Franza BR, Gralnick HR (2003). "Sheehan's syndrome". Pituitary. 6 (4): 181–8. doi:10.1210/jc.2001-020242. PMID 15237929.
  3. Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N (2002). "Pituitary autoimmunity in patients with Sheehan's syndrome". J. Clin. Endocrinol. Metab. 87 (9): 4137–41. doi:10.1210/jc.2001-020242. PMID 12213861.
  4. Abourawi, F (2006). "Diabetes Mellitus and Pregnancy". Libyan Journal of Medicine. 1 (1): 28–41. doi:10.4176/060617. ISSN 1993-2820.

Template:WH Template:WS